Health officials in North Carolina are sounding the alarm over a volatile shift in the illicit drug market as a powerful veterinary tranquilizer known as medetomidine begins to dominate the street supply. Often referred to as Rhino Tranq, this sedative has rapidly overtaken another animal tranquilizer, xylazine, in frequency according to data from the UNC Street Drug Analysis Lab. Experts say the current landscape is becoming increasingly mucky and unpredictable, with users rarely purchasing a single substance but instead consuming cocktails of chemicals where dealers constantly swap out additives without warning.
While medetomidine differs from xylazine in that it typically does not cause severe skin wounds, it brings its own set of harrowing risks. It is significantly more potent and can plunge users into deep, prolonged sedation characterized by slowed heart rates and dangerously low blood pressure. Because it is frequently laced with fentanyl, first responders face a complex challenge during overdoses. While naloxone can restore breathing by reversing the opioid component, it has no effect on medetomidine, meaning a patient may remain unconscious or heavily sedated even after they are technically saved from respiratory failure.
Perhaps most terrifying to medical professionals is what happens when a user attempts to stop taking the drug. Dr. Nabarun Dasgupta of the UNC Street Drug Lab has described medetomidine withdrawal as a nightmare that can land patients in intensive care units for weeks. Unlike traditional opioid withdrawal, this crisis hits fast and hard, manifesting as uncontrollable vomiting, delirium, racing hearts, and extreme hypertension. Doctors report that standard treatments like benzodiazepines often fail to work, leaving clinicians feeling as though they are facing something entirely foreign to modern emergency medicine.
This trend highlights a broader concern among public health advocates regarding how law enforcement handles synthetic drugs. Some experts argue that aggressive crackdowns on previous additives like xylazine simply incentivize illegal manufacturers to find even more dangerous substitutes to fill the gap. As these chemical pivots continue, agencies like the CDC are rushing to provide guidelines for clinicians and jail staff who find themselves unprepared for the violent physiological crashes triggered by this newest addition to the street supply.
